Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Pembrolizumab
Related studies linked through entity extraction aliases.
Study to Evaluate the Efficacy and Safety of Eribulin Mesylate in Combination With Pembrolizumab in Participants With Metastatic Triple-Negative Breast Cancer (mTNBC)
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients
- Status
- TERMINATED
- Phase
- PHASE1
Trial to Evaluate the Safety of Talimogene Laherparepvec Injected Into Tumors Alone and in Combination With Systemic Pembrolizumab MK-3475-611/Keynote-611
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)
- Status
- COMPLETED
- Phase
- PHASE3
Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Testing the PD-1 Inhibitor Pembrolizumab as Maintenance Therapy After Initial Chemotherapy in Metastatic Bladder Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors
- Status
- TERMINATED
- Phase
- PHASE2
Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Study of Pembrolizumab (MK-3475) as First-Line Monotherapy and Combination Therapy for Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (MK-3475-062/KEYNOTE-062)
- Status
- COMPLETED
- Phase
- PHASE3
Trial of pIL-12/MK-3475 in Metastatic Melanoma
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab After SBRT Versus Pembrolizumab Alone in Advanced NSCLC
- Status
- COMPLETED
- Phase
- PHASE2
Pembrolizumab and Cryosurgery in Treating Patients With Newly Diagnosed, Oligo-metastatic Prostate Cancer
- Status
- COMPLETED
- Phase
- NA
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers
- Status
- COMPLETED
- Phase
- PHASE1
Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)
- Status
- COMPLETED
- Phase
- PHASE2